华熙生物
(688363)
| 流通市值：199.17亿 | | | 总市值：199.17亿 |
| 流通股本：4.82亿 | | | 总股本：4.82亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 829,407,051.84 | 4,199,089,274.55 | 3,163,398,568.64 | 2,260,691,517.33 |
| 营业收入 | 829,407,051.84 | 4,199,089,274.55 | 3,163,398,568.64 | 2,260,691,517.33 |
| 二、营业总成本 | 752,718,280.03 | 3,825,862,023.08 | 2,850,484,222.23 | 1,981,640,358.55 |
| 营业成本 | 266,762,450.43 | 1,245,918,494.01 | 927,354,696.07 | 655,733,454.52 |
| 税金及附加 | 5,434,023.14 | 56,248,611.91 | 38,339,961.23 | 27,156,541.16 |
| 销售费用 | 263,396,266.72 | 1,514,819,690.96 | 1,117,246,632.38 | 807,998,012.65 |
| 管理费用 | 117,873,077.5 | 541,749,778.09 | 419,001,012.99 | 275,140,183.32 |
| 研发费用 | 85,785,951.08 | 472,143,898.89 | 361,218,043.67 | 231,101,906.21 |
| 财务费用 | 13,466,511.16 | -5,018,450.78 | -12,676,124.11 | -15,489,739.31 |
| 其中:利息费用 | 2,414,166.05 | 4,146,493.55 | 3,491,105.65 | 1,972,694.3 |
| 其中:利息收入 | 2,185,750.61 | 7,632,886.64 | 5,566,544.62 | 3,757,593.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,229,372.32 | 19,623,286.8 | 850,434.55 | 556,788.66 |
| 加:投资收益 | -4,267,265.76 | -5,471,394.65 | -9,000,543.91 | -5,773,140.64 |
| 资产处置收益 | 20,874.41 | 217,334.91 | 923,350.58 | -445,465.9 |
| 资产减值损失(新) | -44,246.88 | -108,053,142.71 | -47,103,548.91 | -41,390,475.33 |
| 信用减值损失(新) | -11,033,691.28 | -37,453,575.87 | -45,205,263.95 | -27,667,481.57 |
| 其他收益 | 10,763,089.18 | 91,002,552.57 | 78,319,478.04 | 56,704,687.59 |
| 四、营业利润 | 70,898,159.16 | 333,092,312.52 | 291,698,252.81 | 261,036,071.59 |
| 加:营业外收入 | 113,650.84 | 3,853,958.2 | 3,389,971.52 | 1,467,792.29 |
| 减:营业外支出 | 2,992,137.55 | 3,144,265.9 | 3,554,996.33 | 2,179,436.83 |
| 五、利润总额 | 68,019,672.45 | 333,802,004.82 | 291,533,228 | 260,324,427.05 |
| 减:所得税费用 | 3,014,967.1 | 42,653,634.43 | 39,210,348.68 | 39,520,992.58 |
| 六、净利润 | 65,004,705.35 | 291,148,370.39 | 252,322,879.32 | 220,803,434.47 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 65,004,705.35 | 291,148,370.39 | 252,322,879.32 | 220,803,434.47 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 64,654,739.6 | 292,058,565.6 | 252,380,359.37 | 220,851,905.02 |
| 少数股东损益 | 349,965.75 | -910,195.21 | -57,480.05 | -48,470.55 |
| 扣除非经常损益后的净利润 | 57,528,695.51 | 186,400,439.74 | 185,441,230.35 | 173,745,743.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.61 | 0.52 | 0.46 |
| (二)稀释每股收益 | 0.14 | 0.61 | 0.52 | 0.46 |
| 八、其他综合收益 | -20,527,812.3 | 38,976,111.47 | 46,603,668.18 | 51,143,889.08 |
| 归属于母公司股东的其他综合收益 | -20,527,812.3 | 38,976,111.47 | 46,603,668.18 | 51,143,889.08 |
| 九、综合收益总额 | 44,476,893.05 | 330,124,481.86 | 298,926,547.5 | 271,947,323.55 |
| 归属于母公司股东的综合收益总额 | 44,126,927.3 | 331,034,677.07 | 298,984,027.55 | 271,995,794.1 |
| 归属于少数股东的综合收益总额 | 349,965.75 | -910,195.21 | -57,480.05 | -48,470.55 |
| 公告日期 | 2026-04-30 | 2026-04-23 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |